VILOXAZINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H19NO3
Molecular Weight	237.2954
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOc1ccccc1OCC2CNCCO2

InChI

InChIKey=YWPHCCPCQOJSGZ-UHFFFAOYSA-N

InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3

HIDE SMILES / InChI

Molecular Formula	C13H19NO3
Molecular Weight	237.2954
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22454923 | https://www.ncbi.nlm.nih.gov/pubmed/324751 | http://bipolarnews.org/?tag=viloxazine | https://www.ncbi.nlm.nih.gov/pubmed/30924702

Viloxazine is an antidepressant drug was used to treat patients with depression. Viloxazine inhibits noradrenaline uptake. This drug was approved in some Europe countries, but not in the USA, but then it was discontinued because of competition from other drugs. In the frame of drug repositioning, Viloxazine participated in clinical trials for the treatment of attention deficit hyperactivity disorder. Phase II of trials was successfully passed.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium-dependent noradrenaline transporter 38 Target ID: 6530 Gene ID: 6530 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 1227
Sodium-dependent noradrenaline transporter 38 Target ID: 6530 Gene ID: 6530 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 1227

PubMed

Title	Date	PubMed
[Apropos of atypical melancholia with Sustiva (efavirenz)].	2001 May-Jun	11488260
Intravenous antidepressant treatment: focus on citalopram.	2002 Jun	12192466
Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?	2005 Mar	18568121
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].	2006 Jun	16856516
Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach.	2006 Oct 20	16798119
Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma.	2007 Dec 28	18022628
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood.	2007 May	17555643

Patents

Sample Use Guides

In Vivo Use Guide

100 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Jun 25 23:08:57 UTC 2021` Edited by `admin` on `Fri Jun 25 23:08:57 UTC 2021`
Record UNII	5I5Y2789ZF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VILOXAZINE

Official Name

English

VILOXAZINE [INN]

Common Name

English

VILOXAZINE [WHO-DD]

Common Name

English

VILOXAZINE [MI]

Common Name

English

MORPHOLINE, 2-((2-ETHOXYPHENOXY)METHYL)-

Systematic Name

English

(+/-)-2-(O-ETHOXYPHENOXYMETHYL)MORPHOLINE

Common Name

English

VILOXAZIN

Common Name

English

VILOXAZINE [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N06AX09